Carcinoid and neuroendocrine tumors: Building on success

Journal of Clinical Oncology

Volumn 33, Issue 16, 2015, Pages 1855-1863

  Kunz, Pamela L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DACARBAZINE; ETOPOSIDE; EVEROLIMUS; OCTREOTIDE; PASIREOTIDE; PAZOPANIB; PLATINUM; RECOMBINANT ALPHA2B INTERFERON; STREPTOZOCIN; SUNITINIB; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ALGORITHM; BIOLOGICAL THERAPY; CANCER CONTROL; CARCINOID; CARCINOMA; CLINICAL CLASSIFICATION; GASTROINTESTINAL TRACT; HUMAN; LUNG; NEUROENDOCRINE TUMOR; PANCREAS; PATIENT CARE; POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STAGING; TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; ANIMAL; CANCER STAGING; CARCINOID TUMOR; CELL DIFFERENTIATION; CHEMOEMBOLIZATION; GENETICS; METABOLISM; MORTALITY; NEUROENDOCRINE TUMORS; PATHOLOGY; PATIENT SELECTION; PERSONALIZED MEDICINE; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; CELL DIFFERENTIATION; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASM STAGING; NEUROENDOCRINE TUMORS; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84937157320     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.2532     Document Type: Review

References (58)

1. Lawrence B, Gustafsson BI, Chan A, et al: The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1-18, 2011
2. Yao JC, Hassan M, Phan A, et al: One hundred years after "carcinoid": Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063-3072, 2008
3. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al: Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 21:1794-1803, 2010
4. Mocellin S, Nitti D: Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 24:3040-3044, 2013
5. Kulke MH, Siu LL, Tepper JE, et al: Future directions in the treatment of neuroendocrine tumors: Consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 29:934-943, 2011
6. Bosman FT, Carneiro F, Hruban RH, et al: (eds): WHO Classification of Tumours of the Digestive System (ed 4). Lyon, France, International Agency for Research on Cancer, 2010
7. Travis W: The concept of pulmonary neuroendocrine tumours, in Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon, France, International Agency for Research on Cancer Press, 2004
8. Klimstra DS, Modlin IR, Adsay NV, et al: Pathology reporting of neuroendocrine tumors: Application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34:300-313, 2010
9. Chandrasekharappa SC, Guru SC, Manickam P, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 276:404-407, 1997
10. Reichlin S: Secretion of somatostatin and its physiologic function. J Lab Clin Med 109:320-326, 1987
11. Jiao Y, Shi C, Edil BH, et al: DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331:1199-1203, 2011
12. Banck MS, Kanwar R, Kulkarni AA, et al: The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest 123:2502-2508, 2013
13. Francis JM, Kiezun A, Ramos AH, et al: Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 45:1483-1486, 2013
14. Kulke M, Shah M, Benson AB, et al: National Comprehensive Cancer Network Neuroendocrine Tumors Guidelines, Version 1.2015, 2015
15. Kunz PL, Reidy-Lagunes D, Anthony LB, et al: Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42:557-577, 2013
16. American Joint Committee on Cancer (AJCC): AJCC Cancer Staging Handbook: From the AJCC Cancer Staging Manual (ed 7). New York, New York, Springer-Verlag, 2010
17. Strosberg JR, Cheema A, Weber J, et al: Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 29:3044-3049, 2011
18. Strosberg JR, Weber JM, Feldman M, et al: Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 31:420-425, 2013
19. Ellison TA, Wolfgang CL, Shi C, et al: A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: A validation of current staging systems and a new prognostic nomogram. Ann Surg 259:204-212, 2014
20. Qadan M, Ma Y, Visser BC, et al: Reassessment of the current American Joint Committee on Cancer staging system for pancreatic neuroendocrine tumors. J Am Coll Surg 218:188-195, 2014
21. Strosberg JR, Benson AB, Huynh L, et al: Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: A multicenter retrospective chart review study. Oncologist 19:930-936, 2014
22. O'Toole D, Ducreux M, Bommelaer G, et al: Treatment of carcinoid syndrome: A prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 88:770-776, 2000
23. Bruns C, Lewis I, Briner U, et al: SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146:707-716, 2002
24. Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80:47-50, 2004
25. Wolin EM, Jarzab B, Eriksson B, et al: A multicenter, randomized, blinded, phase III study of pasireotide LAR versus octreotide LAR in patients with metastatic neuroendocrine tumors (NET) with disease-related symptoms inadequately controlled by somatostatin analogs. J Clin Oncol 31, 2013 (suppl 15s; abstr 4031)
26. Kulke MH, O'Dorisio T, Phan A, et al: Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide. Endocr Relat Cancer 21:705-714, 2014
27. Rinke A, Müller HH, Schade-Brittinger C, et al: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 27:4656-4663, 2009
28. Caplin ME, Pavel M, Ćwikła JB, et al: Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:224-233, 2014
29. Yao JC, Shah MH, Ito T, et al: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523, 2011
30. Raymond E, Dahan L, Raoul JL, et al: Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501-513, 2011
31. Moertel CG, Hanley JA: Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 2:327-334, 1979
32. Moertel CG, Lefkopoulo M, Lipsitz S, et al: Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 326:519-523, 1992
33. Arnold R, Wittenberg M, Rinke A, et al: Placebo controlled, double blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): Results on long-term survival. J Clin Oncol 31, 2013 (suppl 15s; abstr 4030)
34. Moertel CG, Kvols LK, O'Connell MJ, et al: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 68:227-232, 1991
35. Mitry E, Baudin E, Ducreux M, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351-1355, 1999
36. Sorbye H, Welin S, Langer SW, et al: Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 24:152-160, 2013
37. Welin S, Sorbye H, Sebjornsen S, et al: Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 117:4617-4622, 2011
38. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 48:6977-6985, 1988
39. Susini C, Buscail L: Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol 17:1733-1742, 2006
40. Heppeler A, Froidevaux S, Eberle AN, et al: Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 7:971-994, 2000
41. Kwekkeboom DJ, de Herder WW, Kam BL, et al: Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 26:2124-2130, 2008
42. Wild D, Fani M, Fischer R, et al: Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: A pilot study. J Nucl Med 55:1248-1252, 2014
43. Moertel CG, Rubin J, Kvols LK: Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J Clin Oncol 7:865-868, 1989
44. Kölby L, Persson G, Franzen S, et al: Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 90:687-693, 2003
45. Faiss S, Pape UF, Böhmig M, et al: Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 21:2689-2696, 2003
46. Pavel ME, Hainsworth JD, Baudin E, et al: Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 378:2005-2012, 2011
47. Falconi M, Plockinger U, Kwekkeboom DJ, et al: Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology 84:196-211, 2006
48. Pavel M, Baudin E, Couvelard A, et al: ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95:157-176, 2012
49. Eriksson B, Annibale B, Bajetta E, et al: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90:214-219, 2009
50. Sun W, Lipsitz S, Catalano P, et al: Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 23:4897-4904, 2005
51. Kouvaraki MA, Ajani JA, Hoff P, et al: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 22:4762-4771, 2004
52. Kulke MH, Stuart K, Enzinger PC, et al: Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401-406, 2006
53. Chan JA, Stuart K, Earle CC, et al: Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 30:2963-2968, 2012
54. Chan JA, Blaszkowsky L, Stuart K, et al: A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor. Cancer 119:3212-3218, 2013
55. Ekeblad S, Sundin A, Janson ET, et al: Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 13:2986-2991, 2007
56. Strosberg JR, Fine RL, Choi J, et al: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 117:268-275, 2011
57. Fine RL, Gulati AP, Tsushima D, et al: Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors. J Clin Oncol 32, 2014 (suppl 3; abstr 179).
58. Ellis LM, Bernstein DS, Voest EE, et al: American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol 32:1277-1280, 2014